Curry C J, Stevenson R E, Aughton D, Byrne J, Carey J C, Cassidy S, Cunniff C, Graham J M, Jones M C, Kaback M M, Moeschler J, Schaefer G B, Schwartz S, Tarleton J, Opitz J
Valley Children's Hospital/UCSF, Fresno, California 93703, USA.
Am J Med Genet. 1997 Nov 12;72(4):468-77. doi: 10.1002/(sici)1096-8628(19971112)72:4<468::aid-ajmg18>3.0.co;2-p.
A Consensus Conference utilizing available literature and expert opinion sponsored by the American College of Medical Genetics in October 1995 evaluated the rational approach to the individual with mental retardation. Although no uniform protocol replaces individual clinician judgement, the consensus recommendations were as follows: 1. The individual with mental retardation, the family, and medical care providers benefit from a focused clinical and laboratory evaluation aimed at establishing causation and in providing counseling, prognosis, recurrence risks, and guidelines for management. 2. Essential elements of the evaluation include a three-generation pedigree: pre-, peri-, and post-natal history, complete physical examination focused on the presence of minor anomalies, neurologic examination, and assessment of the behavioral phenotype. 3. Selective laboratory testing should, in most patients, include a banded karyotype. Fragile X testing should be strongly considered in both males and females with unexplained mental retardation, especially in the presence of a positive family history, a consistent physical and behavioral phenotype and absence of major structural abnormalities. Metabolic testing should be initialed in the presence of suggestive clinical and physical findings. Neuroimaging should be considered in patients without a known diagnosis especially in the presence of neurologic symptoms, cranial contour abnormalities, microcephaly, or macrocephaly. In most situations MRI is the testing modality of choice. 4. Sequential evaluation of the patient, occasionally over several years, is often necessary for diagnosis, allowing for delineation of the physical and behavioral phenotype, a logical approach to ancillary testing and appropriate prognostic and reproductive counseling.
1995年10月,美国医学遗传学学院发起了一次共识会议,该会议利用现有文献和专家意见,对智力障碍个体的合理治疗方法进行了评估。虽然没有统一的方案可以取代临床医生的个人判断,但达成的共识建议如下:1. 智力障碍个体、其家庭以及医疗服务提供者都能从有针对性的临床和实验室评估中受益,该评估旨在确定病因,并提供咨询、预后、复发风险以及管理指南。2. 评估的基本要素包括三代家系图谱、产前、产时和产后病史、着重检查是否存在轻微异常的全面体格检查、神经系统检查以及行为表型评估。3. 在大多数患者中,选择性实验室检测应包括染色体核型分析。对于不明原因智力障碍的男性和女性,尤其是存在阳性家族史、一致的身体和行为表型且无主要结构异常的患者,应强烈考虑进行脆性X检测。在有提示性临床和体格检查结果时,应启动代谢检测。对于未明确诊断的患者,尤其是存在神经系统症状、颅骨轮廓异常、小头畸形或大头畸形的患者,应考虑进行神经影像学检查。在大多数情况下,MRI是首选的检测方式。4. 为了诊断,有时需要对患者进行数年的连续评估,以便确定身体和行为表型,采用合理的辅助检测方法,并提供适当的预后和生殖咨询。